Traws Pharma Delays Flu Drug Trial, Triggers 28% After-Hours Stock Drop
TRAW•Traws Pharma shares plunged 28% in after-hours trading after the company postponed its human challenge trial for lead flu candidate tivoxavir marboxil following MHRA concerns. The move comes as both MHRA and FDA placed holds on the drug’s studies and extends the company’s cash runway into Q1 2027.
1. After-Hours Slump Follows Trial Postponement
Shares of Traws Pharma fell about 28% in after-hours trading after the company announced it was postponing the planned human challenge study for its lead flu treatment, tivoxavir marboxil, which would have exposed healthy volunteers to a controlled influenza strain.
2. Regulatory Agencies Place Holds
The United Kingdom’s Medicines and Healthcare products Regulatory Agency raised concerns that led to the study delay, and the U.S. Food and Drug Administration similarly placed the IND application on hold due to questions over toxicology data and potential genetic risks.
3. Backup Antivirals and Financial Outlook
Despite the setback, Traws Pharma emphasized its portfolio of backup influenza antiviral compounds and alternative candidates, maintaining a cash runway extending into the first quarter of 2027 while it addresses regulators’ feedback.
